Antibodies against aberrant glycosylated myeloperoxidase (MPO) have been identified in the sera of 21 of 40 patients with anti-glomerular basement membrane (GBM) disease who did not have MPO-antineutrophil cytoplasmic antibody. Binding of these new antibodies to aberrant glycosylated MPO was not inhibited by intact MPO or GBM antigen. They belonged to the IgG1 subclass and were able to activate complement and induce neutrophil degranulation in vitro. The researchers conclude that aberrant glycosylation alters MPO antigenicity by exposing neo-epitopes and that antibodies against aberrant glycosylated MPO might contribute to kidney damage in vasculitis.
References
Ju, J. et al. Deglycosylation of myeloperoxidase uncovers its novel antigenicity. Kidney Int. http://dx.doi.org/10.1016/j.kint.2016.12.012 (2017)
Rights and permissions
About this article
Cite this article
Carney, E. Abberrant glycosylation alters MPO antigenicity. Nat Rev Nephrol 13, 194 (2017). https://doi.org/10.1038/nrneph.2017.28
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2017.28
